Publications by authors named "Baixin Wu"
Bosn J Basic Med Sci
October 2022
Article Synopsis
- IRAK1/4 is a key kinase in the Toll-like receptor pathway linked to inflammation, making it a target for treating diseases like ulcerative colitis (UC).
- In a study, mice with experimentally induced colitis were treated with varying doses of IRAK1/4 inhibitors, which resulted in significant improvement in disease symptoms and a decrease in pathological damage.
- The findings suggest that the IRAK1/4 inhibitor works by blocking the TLR4/NF-κB pathway, thereby reducing inflammation and preserving the integrity of the intestinal barrier.
